Korean J Ophthalmol.  2006 Dec;20(4):205-209. 10.3341/kjo.2006.20.4.205.

Intravitreal versus Posterior Subtenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema

• Choi YJ
• Oh IK
• Oh JR
• Huh K

• KMID: 754583
• DOI: http://doi.org/10.3341/kjo.2006.20.4.205

Abstract

PURPOSE: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. METHODS: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured. RESULTS: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection. CONCLUSIONS: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.

Keyword

Diffuse diabetic macular edema; Intravitreal injection; Posterior subtenon injection; Triamcinolone acetonide

MeSH Terms

Vitreous Body
Visual Acuity
Triamcinolone Acetonide/*administration & dosage/therapeutic use
Treatment Outcome
Tomography, Optical Coherence
Prospective Studies
Orbit
Middle Aged
Male
Macular Edema, Cystoid/*drug therapy/etiology/pathology
Injections
Humans
Glucocorticoids/*administration & dosage/therapeutic use
Fundus Oculi
Follow-Up Studies
Fluorescein Angiography
Female
Diabetic Retinopathy/*complications/pathology
Aged

Figure

• 

  Fig. 1 Visual acuity in the intravitreal and posterior sub-tenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.

• 

  Fig. 2 Central macular thickness in the intravitreal and posterior subtenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.

• 

  Fig. 3 Changes in the OCT images of representative patient in the intravitreal and posterior subtenon injection groups. In an eye that underwent intravitreal injection, the marked macular edema (A) decreased substantially and the eye showed virtually normal macular configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased substantially with time, and the eye showed virtually normal macular configuration at 3 months (D) after injection.

• 

  Fig. 4 Intraocular pressure in the intravitreal and posterior subtenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.

Reference

1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985. 103:1796–1806.

2. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987. 94:761–774.

3. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse macular oedema: long-term visual results. Ophthalmology. 1991. 98:1594–1602.

4. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no.19. Arch Ophthalmol. 1995. 113:1144–1155.

5. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal Triamcinolone for Refractory Diabetic Macular Edema. Ophthalmology. 2002. 109:920–927.

6. Massin P, Audren F, Haouchine B, et al. Intravitreal Triamcinolone Acetonide for Diabetic Diffuse Macular Edema; Preliminary Results of a Prospective Controlled Trial. Ophthalmology. 2004. 111:218–225.

7. Karacorlu M, Ozdemir H, Karacorlu S, et al. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye. 2004. 19:382–386.

8. Ciardella AP, Klancnik J, Schiff W, et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol. 2004. 88:1131–1136.

9. Jonas JB, Akkoyun I, Kreissig I, et al. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol. 2005. 89:321–326.

10. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular Pressure Elevation after Intravitreal Triamcinolone Acetonide Injection. Ophthalmology. 2005. 112:593–598.

11. Smithen LM, Ober MD, Maranan L, et al. Intravitreal Triamcinolone Acetonide and Intraocular Pressure. Am J Ophthalmol. 2004. 138:740–743.

12. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol. 2005. 19:122–127.

13. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute Endophthalmitis Following Intravitreal Triamcinolone Acetonide Injection. Am J Ophthalmol. 2003. 136:791–796.

14. Ohguro N, Okada AA, Tano Y. Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2004. 242:444–445.

15. Bakri SJ, Kaiser PK. Posterior Subtenon Triamcinolone Acetonide for Refractory Diabetic Macular Edema. Am J Ophthalmol. 2005. 139:290–294.

16. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol. 1987. 130:281–288.

17. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001. 52:37–48.

18. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997. 123:358–363.

19. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of Intravitreal versus Posterior Sub-Tenon's Capsule Injection of Triamcinolone Acetonide for Diffuse Diabetic Macular Edema. Ophthalmology. 2005. 112:1557–1563.

20. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema: A Randomized Clinical Trial. Invest Ophthalmol Vis Sci. 2005. 46:3845–3849.